Top Page
WuXi XDC Cayman, Inc.
(2268)
WuXi XDC Cayman, Inc. (2268) vs. iShares MSCI Hong Kong ETF (EWH)
WuXi XDC Cayman, Inc. Business Overview & Revenue Model
WuXi XDC Cayman, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.09B | 4.05B | 2.12B | 990.42M | 311.13M | 96.35M |
| Gross Profit | 1.68B | 1.24B | 559.56M | 261.08M | 113.49M | 8.08M |
| EBITDA | 1.42B | 1.33B | 420.28M | 151.75M | 77.37M | 7.10M |
| Net Income | 1.33B | 1.07B | 283.54M | 155.73M | 54.93M | 26.30M |
Balance Sheet | ||||||
| Total Assets | 10.62B | 9.12B | 6.74B | 2.50B | 879.75M | 408.47M |
| Cash, Cash Equivalents and Short-Term Investments | 4.54B | 3.97B | 4.05B | 734.97M | 26.32M | 28.39M |
| Total Debt | 1.04B | 496.43M | 2.84M | 77.18M | 24.59M | 0.00 |
| Total Liabilities | 3.18B | 2.48B | 1.28B | 1.02B | 858.87M | 32.79M |
| Stockholders Equity | 7.44B | 6.64B | 5.45B | 1.48B | 20.88M | 375.68M |
Cash Flow | ||||||
| Free Cash Flow | -99.81M | -787.95M | -206.51M | 50.43M | 7.23M | -32.03M |
| Operating Cash Flow | 1.54B | 717.22M | 332.85M | 251.82M | 59.14M | 20.85M |
| Investing Cash Flow | -5.00B | -3.33B | -91.23M | -1.28B | -51.59M | -52.42M |
| Financing Cash Flow | 967.91M | 475.36M | 3.52B | 1.33B | 22.34M | 69.12M |
WuXi XDC Cayman, Inc. Technical Analysis
WuXi XDC Cayman, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$72.52B | 16.64 | 19.62% | ― | ― | ― | |
69 Neutral | HK$307.62B | 21.89 | 25.65% | 1.84% | 11.55% | 64.46% | |
66 Neutral | HK$25.25B | 195.38 | 2.74% | 0.15% | -21.76% | ― | |
62 Neutral | HK$48.87B | 14.14 | 2.72% | 0.80% | -3.81% | -34.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
WuXi XDC Cayman, Inc. Corporate Events
WuXi XDC Cayman Inc., incorporated in the Cayman Islands and listed in Hong Kong, announced that its board of directors will convene on 23 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025 and arrange for their publication. The scheduled board meeting signals the forthcoming release of the company’s full-year financial performance, a key event for investors and other stakeholders tracking the group’s operational progress and governance developments.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$88.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
WuXi XDC Cayman Inc. has issued a positive profit alert, indicating that based on preliminary unaudited figures for 2025, the group expects strong growth across key financial metrics. Revenue for the year to 31 December 2025 is projected to rise by more than 45% from 2024, while gross profit is expected to increase by over 70%, reflecting improved product and service margins and tighter cost management. Adjusted net profit before interest income and expense is forecast to climb by more than 45%, or over 65% when excluding foreign exchange effects, underscoring robust momentum in the company’s core operations. Net profit is anticipated to grow by more than 38% despite adverse foreign exchange and interest rate movements, suggesting an overall strengthening of profitability and operational leverage ahead of the company’s full annual results announcement expected in March 2026.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$90.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
Citigroup Global Markets Asia Limited, on behalf of an offeror, has launched a voluntary conditional cash offer to acquire all issued shares of WuXi XDC Cayman, Inc. not already owned by the offeror and its concert parties, as well as to cancel all outstanding share options, at HK$4.00 per share. The offer price represents a premium of about 99% over the undisturbed closing price of HK$2.01, and the offeror has stated it will not increase either the share offer price or the option cancellation price, positioning this as a potentially major transaction for the offeror and a disclosable transaction for WuXi Biologics while setting a clear ceiling for shareholders and option holders considering whether to tender.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$90.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
WuXi XDC Cayman Inc. announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in January 2026, using the event to share detailed information on its business operations with investors while simultaneously disclosing the same material to the market. The company reported strong business and financial performance in 2025, highlighting a total of 1,291 projects, including 70 newly signed integrated chemistry, manufacturing and controls projects and 10 new process performance qualification projects, which underscore its growing commercial potential. With more than 600 customers served globally, over 120 global IND submissions completed, and 70 projects progressing from discovery to iCMC stage via its ADC CRDMO platform, WuXi XDC is reinforcing its position as a key player in the ADC outsourcing space. The group is also expanding its operational footprint in China and Singapore, with further domestic and overseas sites planned, and it maintains confidence in sustaining its growth momentum into 2026, signaling continued scaling and capacity expansion for stakeholders.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$90.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
WuXi XDC Cayman Inc. announced the successful passing of all proposed resolutions at its extraordinary general meeting held on December 12, 2025. These resolutions included the approval of revised service fees and new master services agreements with WuXi Biologics and WuXi AppTec, which are set to enhance the company’s operational framework and strategic partnerships. The unanimous approval by shareholders indicates strong support for the company’s future plans and collaborations, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$90.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
WuXi XDC Cayman Inc. has announced an extraordinary general meeting to be held on December 12, 2025, to discuss and approve several resolutions related to service agreements with WuXi Biologics and WuXi AppTec. These resolutions include revised maximum service fees and new master services agreements, which are expected to impact the company’s operational framework and strategic partnerships.
The most recent analyst rating on (HK:2268) stock is a Hold with a HK$63.30 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
WuXi XDC Cayman Inc., a company incorporated in the Cayman Islands, has announced revisions to its annual caps for relevant Continuing Connected Transactions (CCT) agreements, the renewal of existing CCT agreements, and the introduction of new CCT agreements. The company has provided supplemental information regarding its pricing policies for the Conjugation Discovery Services Agreement, ensuring that service fees are determined through arm’s length negotiation and are in line with market rates. This move is intended to ensure that transactions are conducted on normal commercial terms and are in the interests of the company and its shareholders.
The most recent analyst rating on (HK:2268) stock is a Hold with a HK$63.30 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
WuXi XDC Cayman Inc. has announced the closure of its register of members in anticipation of an extraordinary general meeting (EGM) scheduled for December 12, 2025. This meeting will allow independent shareholders to vote on the revision and renewal of key service agreements related to antibodies and payload-linkers, which are significant for the company’s ongoing operations and strategic positioning in the biotechnology sector.
The most recent analyst rating on (HK:2268) stock is a Hold with a HK$63.30 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.